Nature Corrects CRISPR Breakthrough for SCN2A Disorders

A correction was made to a recent article published in the scientific journal Nature on September 17, 2025, regarding the use of CRISPR activation for treating SCN2A-related neurodevelopmental disorders. The correction involved a minor error in a figure depicting the Scn2a allele, which has now been corrected in both the HTML and PDF versions of the article. According to the correction notice, in the initial version of the article, the exons in the top line of Fig. 1b were incorrectly labeled as 3, 4, and 5. The error has been corrected to reflect the correct order of 5, 4, and 3. The correction does not affect the overall findings or conclusions of the study. The original article, published on September 17, 2025, explored the potential of CRISPR activation as a therapeutic approach for SCN2A-related neurodevelopmental disorders, including autism spectrum disorders and channelopathies. The study, conducted by researchers at the University of California San Francisco, aimed to develop a novel gene regulation strategy for treating these conditions. Dr. Serena Tamura, one of the authors of the study, acknowledged the importance of accuracy in scientific research. "We strive to maintain the highest level of precision in our work, and we appreciate the opportunity to correct this minor error," she said. The correction is a testament to the rigorous standards of scientific research and the commitment to accuracy that scientists and researchers uphold. The correction does not alter the significance of the study's findings, which highlight the potential of CRISPR activation as a promising therapeutic approach for SCN2A-related neurodevelopmental disorders. The study's findings have significant implications for the development of new treatments for these conditions, which affect millions of people worldwide. While the correction is a minor one, it underscores the importance of attention to detail in scientific research and the ongoing efforts to refine and improve our understanding of these complex conditions. The researchers involved in the study are continuing to explore the potential of CRISPR activation as a therapeutic approach for SCN2A-related neurodevelopmental disorders. Further research is needed to fully understand the efficacy and safety of this approach, but the study's findings offer promising insights into the development of new treatments for these conditions.